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Abstract
Background: The interferon-gamma release assay (IGRA) is more specific than the tuberculin skin test to
discriminate between tuberculosis (TB) and nontuberculous mycobacterial (NTM) diseases. Here we performed a
retrospective study to evaluate the performance of the T-SPOT.TB in patients with NTM diseases.
Methods: Between March, 2013 and Nov, 2015, a total of 58 patients with NTM diseases had a T-SPOT.TB
performed were enrolled, 30 patients had definite NTM diseases, 28 had probable diseases. Their clinicopathological
characteristics were reviewed and analyzed. Cultures for mycobacteria were performed. The indirect proportion
method with Löwenstein–Jensen (L-J) medium was used for first-line drug susceptibility test. T-SPOT.TB assay was
performed according to the manufacturer’s instructions. Data were expressed as mean ± standard deviation
(continuous variables) and as numbers and percentages (categorical variables). The χ2 test was used for
comparisons between proportions.
Results: The average age was 51.8 ± 16.1 years (range 10 to 77 years), 58.6% (34/58) were male. 16.4% (9/55) were
TB-PCR positive. 34 (58.6%) isolates were Mycobacterium intracellulare, ten (17.2%) were Mycobacterium chelonae and
seven (12.1%) were Mycobacterium fortuitum. Fifty-two (89.7%) patients were NTM lung disease, five (8.6%) were
pleural disease, and one (1.7%) lymphadenitis. The total positivity of T-SPOT.TB was 53.4% (31/58) among the whole
group (probable and definite). For probable cases, the T-SPOT.TB assay was positive in 53.5% (15/28); for definite
cases, 16 (53.3%) of 30 definite cases were positive. There was no statistical difference in the positivity rate between
them (P < 0.01).
Conclusions: In the study, we showed that a significant portion of NTM diseases were T-SPOT.TB positive in China.
Although T-SPOT.TB is useful diagnostic method for differentiating TB from NTM diseases, in China, the IGRA assay
show limited value in the discrimination. In addition, further research is needed to investigate the association
between TB infection and treatment for NTM patients.
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Background
The nontuberculous mycobacteria (NTM) are ubiqui-
tous microorganisms found in various environments [1].
NTM can cause both asymptomatic infection and symp-
tomatic disease, lung is the most common site of NTM
infection. It is noteworthy that the prevalence of NTM
disease is increasingly reported worldwide [2]. In China,
the most frequent causative organisms of NTM are
Mycobacterium intracellulare (81.2%), Mycobacterium
kansasii (7.8%) and Mycobacterium fortuitum (4.7%) [3].
Currently, the lack of randomized clinical trials to
guide treatment results in that treatment strategies are
largely based on expert opinion [4, 5]. Meanwhile, the
diagnosis of pulmonary NTM disease is significantly de-
layed in China [6]. NTM diseases share clinical signs
with tuberculosis (TB), causing a clinical dilemma in dif-
ferentiation between NTM infection and TB. Until now,
the Tuberculin skin test (TST) remains to be used for
detecting latent TB infection and an adjunctive test for
active TB. However, the TST suffers from false positivity
in NTM diseases and previous BCG-vaccination [7].
Interferon-gamma (IFN-γ) release assays (IGRAs),
such as T-SPOT.TB, QuantiFERON-TB Gold Test
(QFT-GT), are more specific and are based on the T cell
mediated IFN-γ release after stimulation with specific
Mycobacterium tuberculosis (M.TB) antigens. These tests
have a better specificity worldwide without cross-
reactivity with most NTM [8] and BCG, and a higher
sensitivity compared to the TST for detection of active
TB or latent TB infection [9, 10]. The T-SPOT.TB assay
is based on response to the M.TB specific peptide anti-
gens ESAT-6 and CFP-10 which are located in the re-
gion of difference (RD1). The RD1 is present in
mycobacteria belonging to the M.TB complex (M.TB,
Mycobacterium africanum, Mycobacterium bovis, Myco-
bacterium canettii, Mycobacterium caprae, Mycobacter-
ium microti, Mycobacterium pinnipedii, Mycobacterium
mungi and Mycobacterium orygis) [11] and very few
NTM species also share the RD1 of M.TB complex
(Mycobacterium gastri, Mycobacterium kansasii, Mycobac-
terium marinum, Mycobacterium riyadhense and Myco-
bacterium szulgai) [8, 12, 13]. Therefore, infection with
these strains may result in a positive result of T-SPOT.TB
assay. Due to the high specificity of the IGRAs, some
studies have suggested that it can be used to discriminate
between infection with TB and NTM [14–17].
The goal of this retrospective study is to evaluate the
performance of the T-SPOT.TB in patients with NTM
diseases in a high TB-burden country.
Methods
The protocol was approved by the Ethical Committee of
Shandong Provincial Chest Hospital, written informed
consent was not required because of the retrospective
nature of the investigation.
Between March, 2013 and Nov, 2015, a total of 58 pa-
tients with NTM diseases had a T-SPOT.TB performed
were enrolled, 30 patients had definite NTM diseases, 28
had probable diseases. Their clinicopathological charac-
teristics were reviewed and analyzed.
Cases were defined as “definite” according to the 2007
ATS/IDSA criteria for disease when they had clinical cri-
teria and there were at least two separate positive cul-
tures of sputum samples, or at least one positive culture
from bronchial lavage or lung biopsy [1]. Patients with a
positive NTM culture with a compatible clinical syn-
drome were termed as “probable”. Cultures for myco-
bacteria were performed using Löwenstein–Jensen
medium (L-J) method. The indirect proportion method
with L-J medium was used for first-line drug susceptibility
test (DST) [18].
T-SPOT.TB assay (Oxford Immunote Ltd., Edinburgh,
UK) was performed according to the manufacturer’s in-
structions. Briefly, peripheral blood mononuclear cells
was separated from a whole blood sample and incubated
with the antigens (ESAT-6 and CFP10). The secreted
cytokine by sensitized T cell was captured by specific
antibodies on the membrane. Finally, the cytokine was
detected by a chromogenic spot assay. Following manu-
facture instructions, the result of the testing was catego-
rized “positive” or “negative” by spot count.
Statistical analysis was carried out using SPSS 17.0
software. Data were expressed as mean ± standard devi-
ation (continuous variables) and as numbers and per-
centages (categorical variables). The χ2 test was used for
comparisons between proportions. All statistical tests
are 2-sided at α = 0.05.
Results
Table 1 shows the characteristics of the participants of
this study. The average age was 51.8 ± 16.1 years (range
10 to 77 years), 58.6% (34/58) were male. One hundred
percent (51/51) were HIV-negative. 16.4% (9/55) were
TB-PCR positive. 50.9% (29/57) were positive for acid-
fast bacillus staining. NTM were cultured from sputum
(84.5%), pleural effusion (8.6%), bronchial brushing
(5.2%) and tissues (1.7%). Thirty-four (58.6%) isolates
were Mycobacterium intracellulare, ten (17.2%) were
Mycobacterium chelonae, seven (12.1%) were Mycobac-
terium fortuitum, four (6.9%) were Mycobacterium kan-
sasii, one (1.7%) were Mycobacterium avium, one (1.7%)
were Mycobacterium scrofulaceum and one (1.7%) were
Mycobacterium terrae. Phenotypic DST was performed
on 49 isolates, 48 (98.0%) isolates were resistant to iso-
niazid, 44 (89.8%) resistant to rifampin, 43 (87.8%) resist-
ant to streptomycin, 26 (53.1%) resistant to ethambutol
and 24 (49.0%) resistant to the four drugs.
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Fifty-two (89.7%) patients were NTM lung disease, five
(8.6%) were pleural disease, and one (1.7%) lymphaden-
itis. Thirty-seven (63.8%) patients had cough, 24 (41.4%)
fever, 18 (31.0%) dyspnea and five (8.6%) hemoptysis.
Eight (13.8%) patients were asymptomatic and admitted
for abnormality of chest X-ray. Seven patients have
contact history with a TB patient in the family.
The total positivity of T-SPOT.TB was 53.4% (31/58)
among the NTM group (probable and definite). For
probable cases, the T-SPOT.TB assay was positive in
53.5% (15/28); for definite cases, 16 (53.3%) of 30
definite cases were positive; there was no statistical dif-
ference in the positivity rate between them (P < 0.01).
For NTM strains, 47.1% (16/34) of Mycobacterium intra-
cellulare cases were positive on T-SPOT.TB assay (seven
were probable, nine definite); 70% (7/10) of Mycobacter-
ium chelonae cases were T-SPOT.TB positive (three
were probable, four definite); 57.1% (4/7) of Mycobac-
terium fortuitum cases were T-SPOT.TB positive (all
were definite).
Discussion
China, as one of the 22 high TB-burden countries, M.TB
remains to be the main cause of pulmonary mycobac-
teria diseases. Differentiation between NTM infection
and TB is very difficult. Since IGRAs has the potential
to different TB from NTM diseases, we aimed to evalu-
ate the use of T-SPOT.TB for the discrimination in
China. Surprisingly, in the study, a high proportion of
NTM patients were found to be T-SPOT.TB positive.
The result implied that, 1) TB infection among NTM
diseases was common in China; 2) T-SPOT.TB have
limited value in discrimination of NTM diseases and TB
in China, so the diagnosis of NTM diseases remains to
rely on routine methods (such as culture). To best of
our knowledge, this is the first report for evaluating the
performance of IGRAs in NTM disease in the high
TB-burden country.
It was previously thought that each patient get one
kind of diseases (NTM or TB). Nonetheless, the
development of immunological and molecular methods
Table 1 Demographic and clinical characteristics of probale and definite NTM patients
Probable (n = 28) Definite (n = 30) Total (n = 58)
Age (years) 55.8 ± 13.1 48.0 ± 17.9 51.8 ± 16.1
Sex, male 53.5% (15) 63.3% (19) 58.6% (34/58)
HIV (+) 100% (25/25) 100% (26/26) 100% (51/51)
TB-PCR (+) 10.7% (3/28) 22.2% (6/27) 16.4% (9/55)
AFB staining (+) 63.0% (17/27) 40% (12/30) 50.9% (29/57)
NTM strains
Mycobacterium intracellulare 60.7% (17) 56.7% (17) 58.6% (34/58)
Mycobacterium chelonae 17.9% (5) 16.7% (5) 17.2% (10/58)
Mycobacterium fortuitum 10.7% (3) 13.3% (4) 12.1% (7/58)
Mycobacterium kansasii 10.7% (3) 3.3% (1) 6.9% (4/58)
Mycobacterium avium 0 3.3% (1) 1.7% (1/58)
Mycobacterium terrae 0 3.3% (1) 1.7% (1/58)
Mycobacterium scrofulaceum 0 3.3% (1) 1.7% (1/58)
DST (resistance)
Isoniazid (1 μg/ml) 95.2% (20/21) 100% (28/28) 98.0% (48/49)
Rifampin (50 μg/ml) 85.7% (18/21) 92.9% (26/28) 89.8% (44/49)
Streptomycin (10 μg/ml) 90.5% (19/21) 85.7% (24/28) 87.8% (43/49)
Ethambutol (5 μg/ml) 47.6% (10/21) 57.1% (16/28) 53.1% (26/49)
Firsty-line drugs 42.9% (9/21) 53.5% (15/28) 49.0% (24/49)
Symptoms
Cough 67.9% (19) 60.0% (18) 63.8% (37)
Fever 53.6% (15) 30.0% (9) 41.4% (24)
Dyspnea 25.0% (7) 36.7% (11) 31.0% (18)
Hemoptysis 7.1% (2) 10.0% (3) 8.6% (5)
T-SPOT.TB (+) 53.5% (15/28) 53.3% (16/30) 53.4% (31/58)
HIV human immunodeficiency virus, TB-PCR tuberculosis-polymerase chain reaction, AFB acid fast bacilli, NTM nontuberculous mycobacteria, DST drug
susceptibility test
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has led to increasing reports of mixed infection.
Recently, several studies have reported the occurrence of
mixed infection of TB and NTM [19–22]. In the study,
we also found that 53.4% patients were T-SPOT.TB
positive, and 16.4% NTM patients were TB-PCR posi-
tive. However, a study conducted at our hospital showed
that, in the health care workers, the overall positivity
rate of T-SPOT.TB test was 13.9% (122 out of 879; 95%
CI 11.7–16.3%) [23]. Moreover, in a positive control
group, including 238 culture confirmed TB patients
(aged 39.1 ± 19.5, 64.7% were male), the positivity of
T-SPOT.TB was 86.1% (205/238), our further statistical
analysis showed the positivity of T-SPOT.TB in NTM dis-
eases is lower than in positive control (data not published).
Therefore, our findings should be a direct proof for the
mixed infection. The coexistence of TB and NTM has very
important clinical significance in some patients, mixed
infection may be one of the reasons that may lead to failure
in therapy of NTM diseases, so caution should be exer-
cised [21]. For example, there were five patients (8.6%)
were retreatment NTM disease in our study. Usually,
NTM isolates were resistant to the first-line anti-TB drug.
Therefore, these drugs wouldn’t be the first choice for
treatment of TB patients. But now, since the co-infection
exists, these drugs sensitive for TB but resistant for NTM
stains should be reconsidered. Moreover, an unaccurate
diagnosis of NTM diseases can be made due to the
presence of NTM, which sometimes leads to inappropriate
treatment [21, 24]. In addition, mixed TB and NTM may
also present clinical problems for culture and DST, such as
failure to recognize TB, over-estimation severity of drug
resistance.
Kendall et al. reported that a significant portion of
pulmonary TB patients were identified to have NTM,
particularly in patients with cavitation and those born in
the US [25]. Another US study identified 11.0% of
pulmonary TB patients with NTM species [26].
Simultaneous detection of M.TB and NTM in a speci-
men is possible because NTM may be present as
colonizers or as pathogens and because NTM is ubiqui-
tous in the environment and is isolated frequently in
immunocompromised patients, such as HIV-infected in-
dividuals and patients on immunosuppressive treatment
(for example, Anti-TNF drugs, corticosteroids) [27].
Thus, an analysis was performed by Hwang SM et al., it
was reported that a significant portion of NTM patients
were identified to have TB, ten patients (14.5%) had a
history of TB, mixed cultures (NTM and M.TB) were
present repeatedly in 12 patients (17.4%) [21]. This
research should be the first report addressing the issues
on mixed infection of TB and NTM.
For evaluating diagnostic role of IGRAs in discrimin-
ation of TB and NTM diseases, several studies have been
performed in low TB- burden countries, it showed that
the IGRAs hold potential to discriminate between NTM
and TB infections. A Japanese study showed that QFT-
GT had a mean sensitivity of 86% and a mean specificity
of 94%, the test is a useful diagnostic method for differ-
entiating between them [28]. Hermansen TS et al. found
that QFT-GT was positive in 8% of patients with definite
NTM disease, and in 4% of patients with definite disease
infected with NTM without the RD1 region. [17]. But in
our study, we found that a significant portion of NTM
diseases were T-SPOT.TB positive in China. Similar
result was reported in [14], but the author didn’t address
the issue and contribute it to the cross-reactivity. It
means that in China, the IGRA assay show limited value
in the discrimination between TB and NTM diseases. In
our study, six kinds of NTMs (Mycobacterium intra-
cellulare, Mycobacterium chelonae, Mycobacterium fortui-
tum, Mycobacterium kansasii, Mycobacterium avium and
Mycobacterium terrae) were isolated, only Mycobacterium
kansasii was known to express ESAT-6 and CFP-10 [29].
Our study has some limitations that could have an im-
pact on the results. Bias is more common in retrospect-
ive study. However, bias in this study was minimized by
consecutive cases were enrolled, and patients have equal
chance to participate in the study. The sample size was
small, caution needed when interpreting the results.
Finally current diagnostic methods couldn’t identify true
active TB from these T-SPOT.TB or TB-PCR positive
cases. Therefore, we have no further suggestion on how
to choose appropriate regime for NTM cases with
T-SPOT.TB or TB-PCR positive, but we think the
first-line anti-TB drugs should be considered.
Conclusions
In the study, we showed that a significant portion of
NTM diseases were T-SPOT.TB positive in China. Al-
though T-SPOT.TB was useful diagnostic method for
differentiating TB from NTM diseases in low-TB burden
countries, in China, the IGRA assay show limited value
in the discrimination. In addition, further research is
needed to investigate the association between TB infec-
tion and treatment for NTM diseases.
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